SOURCE: DNAPrint Genomics, Inc.

November 08, 2006 07:00 ET

DNAPrint Genomics EuroDNA™ Test Used as Basis for Reality Show on British Television

Times of London Obtains Results From Program, Publishes Article Speculating Former British Prime Minister Thatcher May Have Middle Eastern DNA

SARASOTA, FL -- (MARKET WIRE) -- November 8, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that the Company's EuroDNA™ product has been employed as an integral part of the British television reality program, "100% English," and that a recent episode of the program has prompted speculation that Dame Margaret Thatcher, Baroness of Kesteven and former Prime Minister of Great Britain, may have Middle Eastern DNA, according to an Oct. 29 article in The Times of London.

The speculation is based on tests administered to Mrs. Thatcher's daughter, Carol Thatcher, who was tested as part of the television program. It was found that Ms. Thatcher's DNA was 24% Middle Eastern in origin, with the remaining 76% listed as Northwestern European. This led to the speculation that either her mother or her father, the late Denis Thatcher, may have Middle Eastern roots, the article said.

The finding has raised the possibility that Mrs. Thatcher may be descended from a Bedouin tribe, or that her origins may date to the desert farmers of ancient Mesopotamia, which centuries ago covered all of Iraq and large portions of contemporary Turkey, Syria and Iran, according to the Times article, which also dubbed Mrs. Thatcher as "The Queen of the Desert" on the basis of her daughter's test results.

According to the article, Ms. Thatcher stated, "Do I know if any of my great-grandfathers had any associations or came from the Middle East? I haven't got a clue. I will do what research I can. I am now very curious."

To date, tests have not been conducted on Mrs. Thatcher, nor had they been conducted on her late husband Denis while he was alive, so it is unknown whether Ms. Thatcher inherited her traits from her mother or father, according to the Times article.

"100% British" is a reality program in Great Britain that takes eight celebrities who believe that they are truly 100% British and then confronts them with the reality of their origins by showing them the results of DNA tests that were conducted using DNAPrint's EuroDNA™ product.

EuroDNA™ is administered in combination with AncestryByDNA™ that specifically measures "European" sub-ancestry, a type of ancestry shared by people who derived from the fertile crescent of the Middle East some 50,000 years ago and spread to occupy Europe, the Middle East, parts of Eurasia and South Asia. EuroDNA™ breaks the European ancestry into four groups and reports percentages for each: Northwestern European, Southeastern European, Middle Eastern and South Asian.

"We are flattered that this British television program should choose DNAPrint's EuroDNA™ product as the basis for the program and for the determination of Carol Thatcher's ancestry," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "This is a testament to the confidence in the product and the precise results that EuroDNA™ yields."

Mr. Gabriel continued, "We encourage everyone to have their DNA tested, either with EuroDNA™ or AncestryByDNA™."

The entire article may be found at The Times of London online:,,2087-2426968_2,00.html.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWitness ™, RETINOME™, AncestryByDNA™ and EuroDNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400
    Ron Stabiner
    The Wall Street Group, Inc.